Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Letter by Forfia and Borlaug regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".

Forfia PR, Borlaug BA.

Circulation. 2012 Feb 28;125(8):e408; author reply e409-10. doi: 10.1161/CIRCULATIONAHA.111.064584. No abstract available.

2.

Letter by Jamous regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".

Jamous FG.

Circulation. 2012 Feb 28;125(8):e407; author reply e409-10. doi: 10.1161/CIRCULATIONAHA.111.066225. No abstract available.

3.

Letter by Gordon et al regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study".

Gordon B, McDiarmid A, MacGowan G.

Circulation. 2012 Feb 28;125(8):e406; author reply e409-10. doi: 10.1161/CIRCULATIONAHA.111.056259. No abstract available.

4.

Pulmonary hypertension in heart failure with preserved ejection fraction: a target for therapy?

Waxman AB.

Circulation. 2011 Jul 12;124(2):133-5. doi: 10.1161/CIRCULATIONAHA.111.038885. No abstract available.

5.

Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.

Guazzi M, Vicenzi M, Arena R, Guazzi MD.

Circulation. 2011 Jul 12;124(2):164-74. doi: 10.1161/CIRCULATIONAHA.110.983866. Epub 2011 Jun 27.

6.

[Oral sildenafil for pulmonary hypertension in neonates].

Gutiérrez Nicolás F, Viña Romero MM, González Carretero P, Merino Alonso J.

Farm Hosp. 2011 May-Jun;35(3):157-8. doi: 10.1016/j.farma.2010.09.003. Epub 2011 Mar 24. Spanish. No abstract available.

PMID:
21439880
7.

How long can we leave patients with pulmonary arterial hypertension on oral drug monotreatment?

Ogawa A, Matsubara H.

Circ J. 2012;76(5):1089-90. Epub 2012 Mar 30. No abstract available.

8.

Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design.

Cooper TJ, Guazzi M, Al-Mohammad A, Amir O, Bengal T, Cleland JG, Dickstein K.

Eur J Heart Fail. 2013 Jan;15(1):119-22. doi: 10.1093/eurjhf/hfs152. Epub 2012 Oct 24.

9.

Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease.

Humpl T, Reyes JT, Erickson S, Armano R, Holtby H, Adatia I.

Cardiol Young. 2011 Apr;21(2):187-93. doi: 10.1017/S1047951110001745. Epub 2010 Dec 8.

PMID:
21138617
10.

Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.

Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ.

Circulation. 2007 Oct 2;116(14):1555-62. Epub 2007 Sep 4.

11.

Ivabradine in pulmonary arterial hypertension: can we delay the need for parenteral prostanoid therapy?

Correale M, Montrone D, Ieva R, Di Biase M, Brunetti ND.

Clin Res Cardiol. 2013 May;102(5):391-3. doi: 10.1007/s00392-013-0541-x. Epub 2013 Feb 7. No abstract available.

PMID:
23389056
12.

Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.

Botha P, Parry G, Dark JH, Macgowan GA.

J Heart Lung Transplant. 2009 Jul;28(7):676-82. doi: 10.1016/j.healun.2009.04.013. Epub 2009 May 13.

PMID:
19560695
13.

eComment. Further study needed.

Quraishi NN, Lemon TI, Black LF.

Interact Cardiovasc Thorac Surg. 2013 Dec;17(6):968. doi: 10.1093/icvts/ivt424. No abstract available.

14.

"Out of the blue"-safety and efficacy of pulmonary hypertension treatment in childhood*.

Kraemer U, Wildschuth E, Tibboel D.

Pediatr Crit Care Med. 2014 May;15(4):377-8. doi: 10.1097/PCC.0000000000000097. No abstract available.

PMID:
24801422
15.

Pulmonary hypertension in heart failure with preserved left ventricular ejection fraction: diagnosis and management.

Ohara T, Ohte N, Little WC.

Curr Opin Cardiol. 2012 May;27(3):281-7. doi: 10.1097/HCO.0b013e32835220b1. Review.

PMID:
22450719
16.

[Potentially deadly: warning about Revatio (sildenafil) taken with nitroglycerine].

Sabourin G.

Perspect Infirm. 2010 Sep-Oct;7(5):42. French. No abstract available.

PMID:
21744634
17.

Impact of sublingual sildenafil on pulmonary hypertension in patients with heart failure.

Freitas Jr AF, Bacal F, Oliveira Jr Jde L, Santos RH, Moreira LF, Silva CP, Mangini S, Carneiro RM, Fiorelli AI, Bocchi EA.

Arq Bras Cardiol. 2009 Feb;92(2):116-26. English, Portuguese, Spanish.

18.

Sildenafil improves clinical and functional status of an elderly postmenopausal female with 'out of proportion' PH associated with left heart disease.

Correale M, Totaro A, Ferraretti A, Di Biase M, Brunetti ND.

Monaldi Arch Chest Dis. 2013 Dec;80(4):193-4.

19.

Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.

Schäfer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H, Kast R, Klein M.

Cardiovasc Res. 2009 Apr 1;82(1):30-9. doi: 10.1093/cvr/cvp002. Epub 2009 Jan 8.

20.

Intraoperative oral sildenafil for management of pulmonary hypertension: a stepping stone to the future.

Augoustides JG.

J Thorac Cardiovasc Surg. 2007 Jul;134(1):267; author reply 267-8. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk